Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review

Capaccione, Kathleen M.; Valiplackal, Jacienta Pailey; Huang, Alice S.; Roa, Tina; Fruauff, Alana; Liou, Connie; Kim, Eleanor; Khurana, Sakshi; Maher, Mary; Ma, Hong; Ngyuen, Pamela; Mak, Serena; Dumeer, Shifali; Lala, Sonali; D’Souza, Belinda; Laifer-Narin, Sherelle; Desperito, Elise; Ruzal-Shapiro, Carrie; Salvatore, Mary M.

doi:10.1016/j.acra.2022.03.007

Cited by 5 publications

(3 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-CTLA-4 treatment is more frequently associated with colitis and hypophysitis whereas pneumonitis and hypothyroiditis are primarily associated with anti-PD-1 treatment. Serious side effects can be treated with high doses of corticosteroids; however, if not addressed early they can be irreversible and fatal [60].…”

Section: Side Effects Of Icismentioning

confidence: 99%

Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer

Jong

Das

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Treatment of non-small cell lung cancer (NSCLC) has undergone a paradigm shift. Once a disease with limited potential therapies, treatment options for patients have exploded with the availability of molecular testing to direct management and targeted therapies to treat tumors with specific driver mutations. New in vitro diagnostics allow for the early and non-invasive detection of disease, and emerging in vivo imaging techniques allow for better detection and monitoring. The development of checkpoint inhibitor immunotherapy has arguably been the biggest advance in lung cancer treatment, given that the vast majority of NSCLC tumors can be treated with these therapies. Specific targeted therapies, including those against KRAS, EGFR, RTK, and others have also improved the outcomes for those individuals bearing an actionable mutation. New and emerging therapies, such as bispecific antibodies, CAR T cell therapy, and molecular targeted radiotherapy, offer promise to patients for whom none of the existing therapies have proved effective. In this review, we provide the most up-to-date survey to our knowledge regarding emerging diagnostic and therapeutic strategies for lung cancer to provide clinicians with a comprehensive reference of the options for treatment available now and those which are soon to come.

show abstract

Section: Side Effects Of Icismentioning

confidence: 99%

Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer

Jong

Das

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, imaging is integral to managing patients receiving immunotherapeutic agents, and a comprehensive understanding of its mechanism, response patterns, and adverse events is essential for accurately interpreting imaging studies. Immune-related adverse events are a new class of side effects caused by abundant upregulation (IRAEs) [ 141 ], furthermore, the author explains that it is compulsory for the practicing radiologist to be able to recognize these events in order to optimally contribute to the care of patients receiving immunotherapy with checkpoint inhibitors [ 142 , 143 ].…”

Section: Main Findings Of the Literature (Review) Questmentioning

confidence: 99%

Intra-Abdominal Malignant Melanoma: Challenging Aspects of Epidemiology, Clinical and Paraclinical Diagnosis and Optimal Treatment—A Literature Review

et al. 2022

View full text Add to dashboard Cite

According to European consensus-based interdisciplinary guidelines for melanoma, cutaneous melanoma (CM) is the most deadly form of dermatological malignancy, accounting for 90% of the deaths of skin cancer patients. In addition to cutaneous melanoma, mucosal melanoma occurs in four major anatomical sites, including the upper respiratory tract, the conjunctiva, the anorectal region, and the urogenital area. As this cancer type metastasizes, a classification used in the current medical literature is the distinction between secondary lesions and primary malignant melanoma of the abdominal cavity. Given that malignant melanoma is the most common cancer that spreads to the gastrointestinal tract, different imaging modalities compete to diagnose the phenomenon correctly and to measure its extension. Treatment is primarily surgery-based, supported by immunotherapy, and prolongs survival, even when performed at stage IV illness. In the end, special forms of malignant melanoma are discussed, such as melanoma of the genito-urinary tract and amelanotic/achromic melanoma. The importance of this present literature review relies on yielding and grouping consistent and relevant, updated information on the many aspects and challenges that a clinician might encounter during the diagnosis and treatment of a patient with intra-abdominal melanoma.

show abstract

“…The other development regards immune checkpoint inhibitors (ICIs), 8 which are drugs that bind to inhibitory receptors and block inhibitory signal transduction, releasing the brakes on the immune system and enhancing the immune response to tumors 8 . Although ICIs can cause immune-related adverse reactions (IRAEs), 9 the IRAE frequency is low. However, malnutrition due to colitis with severe diarrhea, pericarditis, 10 hepatotoxicity, 11 and circulatory disturbance due to IRAEs to lower extremity soft tissue are reported causes of BLE 12,13 .…”

Section: Introductionmentioning

confidence: 99%

Using Compression Therapy to Treat Bilateral Lower Limb Edema in Patients with Lung Cancer: A Case Series

Kayauchi,

Nagatsu,

Satoh

2023

Adv Skin Wound Care

View full text Add to dashboard Cite

Although rare, marked bilateral leg edema (BLE) can occur in patients with lung cancer. Systemic therapy for the underlying disease is important, but adjunct therapy might also be helpful. In this case series, the authors report on treating BLE in patients with lung cancer with compression therapy using elastic stockings and bandages. From April 2013 to March 2022, the authors conducted a retrospective survey of seven patients who developed marked BLE and received compression therapy. They evaluated effects based on improvements in subjective symptoms as well as objective findings 2 months after the start of the therapy. The bandage therapy was useful in patients who were driver-gene negative, but it was not effective in those who already had “progressive disease” with specific agents for their driver genes. No adverse events were observed. Compression therapy, even when attached or detached by nonmedical personnel, may provide favorable effects and should be considered as an adjunct treatment option in this population, in addition to effective systemic cancer therapy. These results indicate that a prospective clinical trial would be worthwhile.

show abstract

Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review

Cited by 5 publications

References 115 publications

Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer

Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer

Intra-Abdominal Malignant Melanoma: Challenging Aspects of Epidemiology, Clinical and Paraclinical Diagnosis and Optimal Treatment—A Literature Review

Using Compression Therapy to Treat Bilateral Lower Limb Edema in Patients with Lung Cancer: A Case Series

Contact Info

Product

Resources

About